newsfilter
← Latest News
GlobeNewswire·

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) (the "Company"), today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with